RoosterBio

Achieve 10-fold #exosome yields with AgentV™-DSP, a powerful downstream processing solution. This chemically defined reagent solves filtration problems by breaking up biological components in conditioned media to prevent filter fouling & particle loss. ➡️roosterbio.com/products/agent…

🔍 How does extracellular vesicle content determine function? In our recent webinar, we explored how orthogonal analytical methods can connect EV composition to activity and enable manufacturing for consistent, scalable therapies. Learn more here⤵️ roosterbio.com/blog/from-form…

📙From tissue donor screening to GMP cell banks and analytics, RoosterBio can help simplify a cellular therapeutic's path to the clinic by bypassing bottlenecks, reducing CMC risks, and saving months of time. This blog shows how.➡️ roosterbio.com/blog/get-your-…

🗓️ Join our upcoming webinar! RoosterBio has established strong alignment across 3 robust, orthogonal analytical methods that allow researchers to test how process changes impact cargo content and function, an important quality attribute for MSC-EVs. ➡️us02web.zoom.us/webinar/regist…

Learn how to unlock the link between EV content and function in MSC research. Join @RoosterBio Inc. for an insightful webinar, EV Content vs Function: Using Analytical Tools to Reveal the Connection, on Tuesday, February 10th at 11:00 AM ET. us02web.zoom.us/webinar/regist…

📙 This blog highlights the work of 2 researchers who used RoosterBio products to rapidly launch first-in-human studies for eye disease and post-COVID lung fibrosis. See how scalable tools and smart partnerships can accelerate cell therapy development.➡️ roosterbio.com/blog/roosterbi…

We continue to be awed by @RoosterBio's leadership in cell culture innovation and the way they simplify processes while enabling scalability: Generate Billions of Xeno-Free Fibroblasts for Your R&D Program: roosterbio.com/products/xeno-…

5️⃣ When Data Blooms: Insights into MSC-EV Bioprocessing ➡️ roosterbio.com/blog/when-data…

4️⃣ MSCs, Exosomes, & Aging ➡️ roosterbio.com/blog/mscs-exos…

📝 Check out RoosterBio's top 5 blog posts of 2025, starting with our most-read entry of the year: 1️⃣ Deference to the Differences Between Fibroblasts & MSCs. ➡️ roosterbio.com/blog/deference…

🔍 Reduce raw material costs, time, and risk with MSC Expansion and Exosome Production Bioreactor Kits built to support scalable manufacturing, from process development through clinical manufacturing, in a variety of bioreactor platforms. Get started here➡️roosterbio.com/product-catego…

📊 One challenge of MSC-EV production is scaling up manufacturing processes to ensure that supply can meet growing demand. Download this poster to learn more about a scalable microcarrier-based process for EV production in a stirred tank bioreactor system. roosterbio.com/resource/isev-…

RoosterBio can help simplify a cellular therapeutic's path to the clinic by bypassing bottlenecks, reducing CMC risks, & saving months of time. This blog shows how getting the right "ducks in a row" can keep the focus on what matters most: the therapeutic. roosterbio.com/blog/get-your-…

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-and… @RoosterBio @SecretomeTx

RoosterBio cells, media, and bioprocess tools help power clinical trials in actual human patients, and in this blog, we highlight 2 researchers who used such products to rapidly launch first-in-human studies for eye disease and post-COVID lung fibrosis.⤵️ roosterbio.com/blog/roosterbi…

🔍 AgentV™-Feed is a specialized bioreactor treatment specifically formulated to reduce microcarrier aggregation during upstream processing and maintain optimal MSC growth in high-yield cell culture. Learn more here-> roosterbio.com/products/agent…

📢 Join our webinar this Thursday hosted by @BioProcessOL to learn about scalable solutions and established processes that advanced therapy programs can utilize to address key challenges associated with clinical manufacturing. Learn more & Register here➡️ event.on24.com/wcc/r/4895339/…

📰 RoosterBio and @SecretomeTx today announced completion of commercial-scale production of Secretome’s lead nCPC, STM-01, currently in clinical trials for the treatment of heart failure with preserved ejection fraction and dilated cardiomyopathy.⤵️ roosterbio.com/press_release/…

RoosterBio and Secretome Therapeutics scaled production of STM-01, showing how progress in exosome manufacturing supports more efficient development of regenerative therapies for heart and neurological diseases. - @RoosterBio exosome-rna.com/roosterbio-and…